Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) announce that Novo Nordisk’s acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right (“CVR”). Each CVR entitles its holder to an additional payment of 6 USD per share in cash (or aggregated value of 0.5 billion USD) upon US regulatory approval of Akero’s lead candidate EFX for the treatment of compensated cirrhosis due to MASH.
Read the full article: Novo Nordisk Has Completed Its Acquisition of Akero Therapeutics //
Source: https://www.globenewswire.com/news-release/2025/12/09/3202389/0/en/Novo-Nordisk-has-completed-its-acquisition-of-Akero-Therapeutics.html?_gl=1*1km0c0i*_up*MQ..*_ga*MTY5ODA4MzAwNy4xNzY1MjkwODM3*_ga_ERWPGTJ5X8*czE3NjUyOTA4MzckbzEkZzAkdDE3NjUyOTA4MzckajYwJGwwJGgw